Tyrosine Kinase Inhibitor Formula 1 Enhances Thyroid Cancer Iodine Uptake
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Anaplastic thyroid cancer is challenging to treat due to suppressed expression of the sodium iodide symporter, leading to reduced iodine uptake and resistance to radioactive iodine therapy, which worsens prognosis and treatment outcomes.
Innovation Solution
A pharmaceutical composition containing a compound of Formula 1, its salt, or solvate, which increases the expression of the sodium iodide symporter in thyroid cancer cells, promoting iodine uptake and killing cancer cells, thereby treating or preventing thyroid cancer.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a tyrosine kinase activity inhibitor is used to treat thyroid cancer, then iodine uptake is promoted and cancer cells are killed, but the compound may cause unwanted side effects and has not been fully evaluated for safety and efficacy in humans
Solution Approach 1:
The patent modifies the chemical structure of existing tyrosine kinase inhibitors to create Formula 1 compounds with optimized pharmacological properties. These structural parameter changes aim to enhance tumor-specific activity while reducing off-target effects and toxicity, thereby improving the risk-benefit ratio for human treatment.
Solution Approach 2:
The patent identifies and utilizes sodium iodide symporter (NIS) as a mediator mechanism. By increasing NIS expression in thyroid cancer cells, the compound enables enhanced radioactive iodine uptake, which serves as both a treatment mechanism and a potential biomarker for monitoring treatment response in patients.
2Reliability
If the sodium iodide symporter expression is increased to promote iodine uptake, then cancer cell killing is enhanced, but the mechanism is not fully understood and may have unintended consequences
Solution Approach 1:
The patent proposes using sodium iodide symporter expression levels as a feedback mechanism to monitor treatment response. By measuring NIS expression changes in tumor cells, clinicians can assess whether the therapy is effectively increasing iodine uptake capability, allowing for real-time adjustment of treatment protocols based on measurable biological responses.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition effectively increases iodine uptake in thyroid cancer cells, enhancing the effectiveness of radioactive iodine therapy and reducing colony-forming ability in cancer cells, offering a potential treatment for both differentiated and undifferentiated thyroid cancers.
Implementation Method 1
Sodium iodide symporter (NIS) is an intrinsic transmembrane glycoprotein, and co-transports two sodium cations (Na2+) and one iodine anion (I−) across the basolateral membrane of thyroid follicular cells
Implementation Method 2
Unlike differentiated thyroid cancer, anaplastic carcinoma does not exhibit the characteristics of thyroid follicular cells, such as iodine uptake and thyroglobulin synthesis, and is resistant to radioactive iodine (RAI) therapy due to the reduced iodine uptake thereof
Data Source
AI summary
A pharmaceutical composition containing a tyrosine kinase activity inhibitor as an active ingredient may increase the expression of sodium iodide symporter in thyroid cancer cells, thereby promoting iodine uptake and killing thyroid cancer cells. Thus, the composition may be useful for the treatment of thyroid cancer.